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Abstract A range of bis-heterocyclic derivatives based on novel
morpholinone and triazole heterocycles was prepared from iodo-
morpholinone. The key step in our strategy is a one-pot procedure
based upon copper-catalysed alkyne-azide cycloaddition (CuAAC) from
iodo-morpholinone.
Key words click chemistry, iodolactonization, morpholinones, azides,
1,2,3-triazole, one-pot procedure
The synthesis of five- and six-membered nitrogen-
containing heterocycles, such as morpholinones and 1,2,3-
triazoles, has received considerable attention, and these
structures constitute important classes of biologically ac-
tive compounds.
Various morpholinone-containing compounds have
been reported in the past decade with a range of biological
properties (Scheme 1). For example, compound A exhibits
antifungal and antibacterial activities against four bacteria
and seven fungal species1 and morpholinone B was recently
found to be an inhibitor of the MDM2–p53 protein–protein
interaction.2 It is important to note that 1,2,3-triazole based
heterocycles have become a cornerstone of medicinal
chemistry because of their important biological activities.
For example, compound C exhibits potent anticancer activi-
ty,3 compound D was found to have good TNF- inhibitory
activity,4 antiviral compound E exhibits cytostatic activity
in the high micromolar range,5 and compound F shows po-
tent antibacterial activity against both Gram-positive and
Gram-negative bacteria.6 In addition, a series of thiazoli-
dinediones with triazole substitution show antidiabetic and
anticancer activity properties.7
Given the promising biological properties and synthetic
applications of these heterocycles, it appeared interesting
to consider the combination of these moieties, with the aim
to access novel more biologically effective compounds. As a
consequence, the development of effective and practical
methods for the construction of morpholines with 1,2,3-
triazoles units appeared to be a worthwhile goal.
In our previous work, we have synthesized numerous
heterocycles by using coupling/cyclization tandem reac-
tions.8 In a continuation of our research devoted to the de-
velopment and diversification of new classes of heterocy-
cles, we report herein the construction of iodomorpholi-
none 5 through electrophilic iodocyclization of acid 2. In
addition, introduction of an iodo- functionality provides a
useful route for the synthesis of novel morpholinones, in-
corporating the 1,2,3-triazole moiety, with good yields.
Initially, the starting acids 2 and 4 were prepared from
allylamine in three steps (Scheme 2). Allylamine was to-
sylated under standard conditions, providing the corre-
sponding tosyl-functionalized amine. This amine was then
alkylated by following Raghunathan’s protocol using ethyl
bromoacetate, affording ethyl N-allyl-N-tosylglycinate 1 in
80% yield over two steps.9 Saponification of ester 1 was
achieved using 12% KOH, leading to the corresponding acid
2 in quantitative yield. The synthesis of compound 4 was
achieved in two steps. First, the N-tosylated allyl amine was
reacted with methyl acrylate in MeCN in the presence of a
substoichiometric amount of 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU), resulting in an aza-Michael addition reaction,
as developed by Kim’s group.10 Having synthesized the ester
3 in good yield (88%), the next task was to convert the ester
into its corresponding acid. The saponification of ester 3
was achieved with LiOH in a MeOH/H2O mixture to afford
the desired acid 4 in quantitative yield. Compounds 3 and 4
were characterized by comparison with the published NMR
spectra (see the Supporting Information).11,12Georg Thieme Verlag  Stuttgart · New York — SynOpen 2018, 2, 298–305
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A. Mayooufi et al. PaperSyn OpenScheme 2  Preparation of acids 2 and 4
We next explored the reactivity of amino acid 2 in the
iodolactonization reaction. Iodocyclization of alkynes or
alkenes represents a useful method for the preparation of
important heterocycles, and a number of methods have
been reported for the construction of functionalized cyclic
compounds through halolactonization such as azetidines
and pyrrolidines,13 benzo[a]phenazines,14 lactones,15 oxaz-
olidin-2-ones,16 and other heterocycles.17 The results of the
iodolactonization of 2 are presented in Table 1. Initial ex-
periments were carried out using I2 (2 equiv) as the electro-
phile and Na2CO3 (3 equiv) as the base in CHCl3 at room
temperature (entry 1). Under these conditions, iodo-mor-
pholinone 5 was obtained while some starting material re-
mained (20%). We further tested ICl, N-bromosuccinimide
(NBS) and NIS as electrophiles instead of iodine in this reac-
tion without changing other factors (entries 2–4) but a de-
crease in the yield of the desired product 5 was noted along
with 20% of starting material remaining. Only a complex
mixture was obtained on increasing the temperature and
only traces of the desired product 5 were isolated (entry 5).
Changing CHCl3 to tetrahydrofuran (THF) gave a similar re-
sult (entry 6). Different bases, such as NaH and NaOH (en-
tries 7–8) gave similar results, while no reaction occurred
when Et3N was used as the base. However, we were pleased
to find that the addition of AgNO3 (1 equiv) provided 5 se-
lectively and in high yield (86%) (entry 10).18 Subsequent
testing showed that increasing the quantity of AgNO3 did
not improve the yield (entry 11). On the basis of these re-
sults, the optimum conditions were established as Na2CO3
(2 equiv), I2 (1.5 equiv) and AgNO3 (1 equiv) in CHCl3 at
room temperature (entry 12). Addition of silver nitrate
probably allows an ionic reaction,19 and precipitation of AgI
from the reaction medium will prevent iodide attacking the
intermediate 5′, avoiding the formation of bis-iodinated by-
products. Subsequently, regioselective intramolecular nuc-
leophilic attack of the oxygen then proceeds via a 6-exo-tet-
ring-closing pathway to form iodo-morpholinone 5.
The successful synthesis of iodomorpholinone 5 led us
to investigate the iodocyclization of 3-aminopropanoic acid
4. Thus, acid 4 was treated with I2 (1.5 equiv), Na2CO3 (2
equiv) and AgNO3 (1 equiv) in CHCl3 at 25 °C and, after 2
hours, complete iodolactonization was achieved, leading to
the iodo-1,4-oxazepan-7-one 6 in 56% yield (Scheme 3). It
should be noted that product 6 is unstable. This product
must be immediately purified, and it degrades quickly even
when stored in the refrigerator.
Scheme 3  Iodocyclization of acid 4
Scheme 1  Selected biologically active triazole and morpholinone units and retrosynthetic strategy for the sequential synthesis of morpholinones in-
corporating the 1,2,3-triazole moiety
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groups into the morpholinone scaffold through CuAAC-
based multicomponent reactions (MCR). MCRs are import-
ant and effective in carbon–nitrogen bond formation be-
cause of their considerable economic and ecological inter-
ests.20 These reactions have become important tools for the
organic chemist to generate complex molecules that find
many applications in drug discovery.21 In this context, the
reactivity of halomorpholinones has been widely studied
with sodium azide and terminal alkynes by using this one-
pot two-step sequence. Although we tested various condi-
tions for the synthesis of 1,2,3-triazoles that are described
in the literature, in our case no desired product was ob-
served.22 On the basis of these results, we turned our atten-
tion to the preparation of novel morpholinones, incorporat-
ing the 1,2,3-triazoles moiety through the more classical
two-step route, as shown in Scheme 4.
Scheme 4  Synthetic routes towards triazole-linked morpholinone 8
Thus, we examined nucleophilic substitution of the re-
maining iodide to introduce the azide group.13,23 In our ini-
tial attempt, we tested the influence of the solvent (Table 2,
entries 1–3 and entries 6–7) and found that protic solvents,
such as H2O and MeOH, led to degradation of product 7,
while the use of aprotic solvents, such as acetone, DMF and
MeCN resulted in a low yield of 7 (30%). Moreover, we found
that heating the reaction only afforded a complex mixture
(entries 4 and 8). An increase in the quantity of NaN3 and
reaction time did not improve the yield of this reaction (en-
try 5). In an attempt to increase the yield of 7, we treated
iodo-morpholinone 5 with sodium azide in the presence of
various additives (entries 9–11)24 and found that product 7
could be obtained from 5 in a very high yield (90%) in the
presence of 18-crown-6. However, further investigation
showed that, whereas increasing the amount of the latter
reduces the reaction time, it did not give a better yield (en-
tries 12 and 13). In this context, it is important to note that
various attempts to introduce an azide group into sub-
strates produced by iodolactonization are reported in the
literature to result in incomplete reaction.13 Unfortunately,
the iodo-1,4-oxazepan-7-one 6, in contrast to iodomor-
pholinone 5, could not be transformed into the desired
Table 1  Optimization of Iodocyclization
En-
try
Electro-
phile 
(equiv)
Solvent Base (equiv) Temp 
(°C)
Additive 
(equiv)
Yield (%)a
1 I2 (2) CHCl3 Na2CO3 (3) rt – 55
2 NBS (2) CHCl3 Na2CO3 (3) 50 – –b
3 ICl (2) CHCl3 Na2CO3 (3) rt – 50
4 NIS (2) CHCl3 Na2CO3 (3) rt – 43
5 I2 (2) CHCl3 Na2CO3 (3) 50 – tracec
6 I2 (2) THF Na2CO3 (3) rt – 51
7 I2 (2) CHCl3 NaH (1.5) 0 – 48
8 I2 (2) CHCl3 NaOH (3) 50 – 45
9 I2 (2) CHCl3 Et3N (3) rt – –b
10 I2 (2) CHCl3 Na2CO3 (3) rt AgNO3 (1) 86
11 I2 (2) CHCl3 Na2CO3 (3) rt AgNO3 (1.5) 84
12 I2 (1.5) CHCl3 Na2CO3 (2) rt AgNO3 (1) 86
a Isolated yield after column chromatography.
b Starting material.
c Complex mixture.
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Table 2  Optimization Studies of the Reaction between Sodium Azide 
and Morpholinone 5
Entry Additive (equiv) Solvent NaN3 
(equiv)
Temp 
(°C)
Yield (%)a
1 – MeOH/H2O 3 rt –b
2 – MeOH 3 60 –b
3 – acetone 3 rt 30c
4 – acetone 3 45 –b
5 – acetone 6 rt 30c,d
6 – DMF 3 rt 30c
7 – MeCN 3 rt 30c
8 – DMF 3 75 –b
9 18-crown-6 (0.5) acetone 3 rt 90
10 TBAI (0.5) acetone 3 rt 72
11 TBAF (0.5) acetone 3 rt 70
12 18-crown-6 (1) acetone 3 rt 90e
13 18-crown-6 (1.5) acetone 3 rt 90e
a Isolated yield.
b Degradation.
c Starting material 5 was recovered in 30% yield.
d 72 h (time of reaction).
e 18 h (time of reaction).
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18-crown-6), presumably because of the instability of the
iodo-1,4-oxazepan-7-one 6.
In the next phase of the study, we wished to generate
1,2,3-triazole derivatives involving a 1,3-dipolar cycloaddi-
tion using azido morpholinone 7 as the starting material.
Many protocols for the synthesis of 1,2,3-triazoles based on
copper(I) catalysts have been reported.25 In our initial at-
tempt, CuSO4·5H2O (10 mol%), was used as catalyst in the
presence of sodium ascorbate (20 mol%) and phenylacety-
lene (1.5 equiv) in toluene/H2O (3:1) at room temperature;
wherein 8a was obtained in a moderate yield (50%). An at-
tempt to use copper(I) iodide under the same conditions
was made, but again afforded moderate yields, as was the
case with copper sulfate. We further examined the effect of
solvents on the cycloaddition reaction (1:3 THF/H2O, tolu-
ene/H2O, DMF/H2O, CHCl3/H2O and CH2Cl2) and the best re-
sults were obtained when the reaction was carried out in
either CH2Cl2 or CHCl3/H2O (Scheme 5). Under these condi-
tions, compound 8a was obtained in good yield (90%).
Scheme 5  1,3-Dipolar cycloaddition between 7 and phenylacetylene
Having established that morpholinone 5 can be trans-
formed into 1,2,3-triazole derivatives in a two-step proce-
dure, we decided to investigate the ‘one-pot’ cascade
(Scheme 6) of the two previously defined steps (Scheme 4)
and we found the presence of 18-crown-6 to be crucial for
the azide substitution reaction to take place. In this context,
iodomorpholinone 5 was subjected to the copper-cata-
lyzed-multicomponent reaction in the presence of 18-
crown-6 using phenylacetylene and sodium azide under the
previously defined conditions. As expected, under these
conditions (Scheme 6), the multicomponent click reaction
worked well and the targeted 1,2,3-triazole 8a was ob-
tained in 82% yield. It was found that 18-crown-6 is indis-
pensable for this three-component reaction. This one-pot
reaction led to the isolation of the desired product 8a with a
similar yield to the two-step procedure (81%). To demon-
strate the generality of this one-pot morpholinone-triazole
synthesis reaction, a range of substituted 1,2,3-triazoles de-
rivatives 8a–k were prepared in moderate to excellent
yields by using the multicomponent reaction of iodomor-
pholinone 5 and sodium azide with various terminal
alkynes.
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A. Mayooufi et al. PaperSyn OpenIn summary, we have developed an efficient and general
methodology for the synthesis of novel six-and seven-
membered iodo heterocycles through electrophilic iodocy-
clization. We have also demonstrated that the resulting six-
membered iodomorpholinone 5 afforded a novel series of
heterocyclic derivatives based on morpholinone and tri-
azole heterocycles, prepared using a CuAAC one-pot proce-
dure in the presence of 18-crown-6. Further investigations
concerning the scope of applications are ongoing in our lab-
oratory.
All reactions were carried out under an argon atmosphere in dried
glassware. THF was distilled under argon from sodium benzophenone
ketyl. Dimethylformamide was dried and freshly distilled from calci-
um hydride. Other chemicals were purchased from Sigma–Aldrich,
Alfa Aesar, Fluorochem or ABCR and used without further purifica-
tion. Reactions were monitored by TLC with Merck silica gel 60 F254.
TLC plates were visualized using UV light (254 nm) or staining with
KMnO4. Column chromatography was performed on silica gel (40–63
m) using mixtures of EtOAc and petroleum ether (35–60 °C fraction)
as eluent. 1H NMR spectra were recorded with a Bruker Avance 300
(300 MHz) NMR spectrometer, using as internal deuterium lock the
solvents CDCl3 ( 7.26 ppm), (CD3)2CO ( = 2.05 ppm) or (CD3)2SO ( =
2.54 ppm). Chemical shifts are quoted in ppm (H, C). Peak multiplic-
ities are defined as: s = singlet, d = doublet, t = triplet, q = quartet,
quint = quintet, sext = sextet, m = multiplet and br = broad. Coupling
constants (J) are reported in Hz. 13C NMR spectra were recorded at 75
MHz on the same instrument, using the solvent peak at as reference
CDCl3 ( = 77.16 ppm), (CD3)2CO ( = 29.85 ppm) or (CD3)2SO ( =
39.52 ppm). 19F NMR spectra were recorded at 282 MHz on the same
instrument, using the CFCl3 as the internal reference ( = 0.0 ppm).
Mass spectra were obtained with a Hewlett Packard 5988A by direct
inlet at 70 eV. HRMS were obtained with a LCMS-IT-TOF mass spec-
trometer under ESI. Infrared spectra were recorded with a Perkin–
Elmer Spectrum One spectrophotometer with the sample being pre-
pared as a thin film on a diamond ATR module. Absorption maxima
(max) are quoted in wavenumbers. Melting points are uncorrected.
Synthesis of 6-(Iodomethyl)-4-tosylmorpholin-2-one (5)
In a round-bottom flask containing carboxylic acid 2 (1 equiv, 300 mg,
1.11 mmol) and CHCl3 (25 mL) were added sodium carbonate (2
equiv, 236 mg, 2.23 mmol), iodine (1.5 equiv, 424 mg, 1.67 mmol) and
silver nitrate (1 equiv, 189 mg, 1.11 mmol). The mixture was stirred 2
h at r.t., quenched with a saturated solution of Na2S2O3 (30 mL) then
extracted with dichloromethane (3 × 25 mL). The combined organic
phases were washed with brine (3 × 10 mL), dried over MgSO4, fil-
tered and evaporated under reduced pressure to yield 5.
Yield: 258 mg (86%); yellow solid; mp 174–175 °C; Rf = 0.53 (EtO-
AC/PE = 1:4).
1H NMR (300 MHz, DMSO-d6):  = 7. 68 (d, J = 7.8 Hz, 2 H), 7.40 (d, J =
7.8 Hz, 2 H), 4.52–4.58 (m, 1 H), 4.03 (d, J = 17.7 Hz, 1 H), 3.76 (d, J =
12.9 Hz, 1 H), 3.68 (d, J = 17.7 Hz, 1 H), 3.39–3.27 (m, 2 H), 3.07 (dd,
J = 7.7, 12.9 Hz, 1 H), 2.47 (s, 3 H).
13C NMR (75 MHz, DMSO–d6):  = 163.6, 145.26, 131.55, 130.44,
127.91, 77.16, 46.79, 46.56, 21.73, 1.74.
HRMS (ESI): m/z [M + H]+ calcd for C12H15INO4S: 395.97610; found:
395.97568.
Synthesis of 2-(Iodomethyl)-4-tosyl-1,4-oxazepan-7-one (6)
In a round-bottom flask containing carboxylic acid 4 (1 equiv, 300 mg,
1.059 mmol) and CHCl3 (25 mL) were added sodium carbonate (2
equiv, 224 mg, 2.12 mmol), iodine (1.5 equiv, 403 mg, 1.59 mmol) and
silver nitrate (1.5 equiv, 180 mg, 1.06 mmol). The mixture was stirred
for 2 h at r.t., quenched with a saturated solution of Na2S2O3 (30 mL)
and extracted with dichloromethane (3 × 25 mL). The combined or-
ganic phases were washed with brine (3 × 10 mL), dried over MgSO4,
filtered and evaporated under reduced pressure.
1H NMR (300 MHz, DMSO-d6):  = 7.68 (d, J = 8.17 Hz, 2 H), 7.38 (d, J =
8.17 Hz, 2 H), 4.48–4.54 (m, 1 H), 4.24–4.3 (dd, J = 1.8 Hz, J = 14.47 Hz,
1 H), 4.03–4.11 (m, 1 H), 3.28–3.41 (m, 2 H), 2.71–3.04 (m, 4 H), 2.47
(s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 163.51, 145.21, 131.39, 130.35,
127.81, 77.27, 53.57, 46.71, 46.48, 21.6, 1.76.
HRMS (ESI): m/z [M + H]+ calcd for C13H17INO4S: 409.99175; found:
409.99147.
Synthesis of 6-(Azidomethyl)-4 tosylmorpholin-2-one (7)
A mixture of the appropriate 6-(iodomethyl)-4-tosylmorpholin-2-
one 5 (300 mg, 0.76 mmol), sodium azide (148 mg, 2.28 mmol), 18-
crown-6 (100 mg, 0.38 mmol) and acetone (20 mL) was stirred at r.t.
until completion of the reaction (TLC). The solvents were evaporated
under reduced pressure, and the crude product was then poured into
water, extracted with CH2Cl2 (3 × 40 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. The crude product was purified
by silica gel chromatography using PE/EtOAc (6:1) mixture as eluent.
1H NMR (300 MHz, CDCl3):  = 7.67 (d, J = 8.3 Hz, 2 H), 7.40 (d, J =
8.3 Hz, 2 H), 4.68–4.61 (m, 1 H), 4.11 (dd, J = 1.1, 17.6 Hz, 1 H), 3.67–
3.58 (m, 3 H), 3.53 (dd, J = 4.4, 13.2 Hz), 2.94 (dd, J = 8.6, 12.7 Hz, 1 H),
2.47 (s, 3 H).
13C NMR (75 MHz, CDCl3):  = 163.52, 145.29, 131.34, 130.43, 130.28,
127.91, 76.77, 51.68, 46.97, 44.25, 21.71.
HRMS (ESI): m/z [M + H]+ calcd for C12H15IN4O4S: 311.08085; found:
311.08011.
Synthesis of Triazoles; General Procedures
Method A
Finely powdered CuSO4·5H2O (16 mg, 10 mol%) and sodium ascorbate
(26 mg, 20 mol%) were slowly added to a stirred solution of 6-(azi-
domethyl)-4-tosylmorpholin-2-one 7 (200 mg, 0.64 mmol) and ter-
minal alkyne (0.96 mmol, 1.5 equiv) in H2O/CHCl3 (3:1 = 15 mL/5 mL)
at 0–10 °C. The mixture was then allowed to reach r.t. and TLC moni-
toring was used to follow reaction progress. The mixture was filtered,
concentrated and diluted with water (30 mL). The aqueous layer was
extracted with CHCl3 (3 × 20 mL), the combined organic layers were
washed with H2O and then with brine, dried over Na2SO4, filtered and
concentrated under vacuum. The crude products were crystallized
from various solvents or purified by flash chromatography over silica
gel (eluent CHCl3/MeOH = 88:12) to afford the desired pure triazole
product.
Method B
6-(Iodomethyl)-4-tosylmorpholin-2-one 5 (789 mg, 2 mmol) was dis-
solved in H2O/CHCl3 (3:1 = 22.5 mL/7.5 mL). Sodium azide (390 mg, 6
mmol) and 18-crown-6 (264 mg, 1 mmol) were then added to the
solution and the suspension was stirred for 30 min. The mixture was
degassed at 0 °C, then the terminal alkyne (4.0 mmol, 2 equiv), sodi-Georg Thieme Verlag  Stuttgart · New York — SynOpen 2018, 2, 298–305
303
A. Mayooufi et al. PaperSyn Openum ascorbate (79 mg, 0.4 mmol, 0.2 equiv) and CuSO4·5H2O (100 mg,
0.4 mmol, 0.2 equiv) were added to the mixture which was then
stirred for 24 h. The reaction was quenched by the addition of satu-
rated aqueous NH4Cl (20 mL) and the mixture was stirred for a further
15 min. The mixture was filtered through a pad of Celite® and the fil-
trate was extracted with EtOAc (3 × 40 mL). The combined organic
layers were washed with brine, dried over Na2SO4, filtered and con-
centrated under reduced pressure. The crude product was then puri-
fied by recrystallization or by flash chromatography on silica gel us-
ing PE/EtOAC as the eluent.
6-[(4-Phenyl-1H-1,2,3-triazol-1-yl)methyl]-4-tosylmorpholin-2-
one (8a)
According to general procedure B, compound 8a was isolated after re-
crystallization (EtOH).
Yield: 675 mg (82%); white solid; mp 213–214 °C; Rf = 0.35 (EtOAC/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.54 (s, 1 H), 7.83 (d, J = 7.75 Hz,
2 H), 7.69 (d, J = 7.75 Hz, 2 H), 7.45 (m, 4 H), 7.34 (t, J = 7.3 Hz, 1 H),
5.00–5.05 (m, 1 H), 4.80 (dd, J = 3.5, 14.6 Hz, 1 H), 4.72 (dd, J = 7.3,
14.6 Hz, 1 H), 4.03 (d, J = 17.2 Hz, 1 H), 3.77 (dd, J = 3.0, 12.3 Hz, 1 H),
3.73 (d, J = 17.2 Hz, 1 H), 3.07 (dd, J = 8.9, 12.5 Hz, 1 H), 2.38 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 164.21, 146.39, 144.46, 131.71,
130.54, 130.21, 128.98, 128.01, 127.71, 125.2, 122.42, 75.75, 50.71,
46.49, 43.53, 21.04.
HRMS (ESI): m/z [M + H]+ calcd for C20H21N4O4S: 413.12780; found:
431.12656.
6-{[4-(p-Tolyl)-1H-1,2,3-triazol-1-yl]methyl}-4-tosylmorpholin-2-
one (8b)
According to general procedure B, compound 8b was isolated after re-
crystallization (EtOH).
Yield: 681 mg (80%); white solid; mp 191–192 °C; Rf = 0.38 (EtOAC/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.47 (s, 1 H), 7. 72 (d, J = 6.4 Hz,
2 H), 7.69 (d, J = 6.4 Hz, 2 H), 7.45 (d, J = 8.1 Hz, 2 H), 7.26 (d, J =
8.1 Hz, 2 H), 5.03–4.98 (m, 1 H), 4.02 (d, J = 18.1 Hz, 1 H), 3.76 (dd, J =
3.5, 11.7 Hz, 1 H), 3.75 (d, J = 18.1 Hz, 1 H), 3.06 (dd, J = 8.9, 12.5 Hz,
1 H), 2.38 (s, 3 H), 2.32 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 164.28, 145.52, 137.41, 131.75,
130.28, 129.58, 127.8, 127.77, 125.2, 122.04, 75.82, 50.73, 46.53,
43.59, 21.1, 20.91.
HRMS (ESI): m/z [M + H]+ calcd for C21H23N4O4S: 427.14345; found:
427.14241.
6-{[4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl]methyl}-4-to-
sylmorpholin-2-one (8c)
According to general procedure B, compound 8c was isolated after re-
crystallization (EtOH).
Yield: 680 mg (77%); white solid; mp 225–226 °C; Rf= 0.37 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.42 (s, 1 H), 7.75 (d, J = 8.8 Hz,
2 H), 7.69 (d, J = 8.2 Hz, 2 H), 7.46 (d, J = 8.2 Hz, 2 H), 7.02 (d, J =
8.8 Hz, 2 H), 5.04–4.96 (m, 1 H), 4.77 (dd, J = 3.9, 14.5 Hz, 1 H), 4.69
(dd, J = 7.4, 14.5 Hz, 1 H), 4.03 (d, J = 17.1 Hz, 1 H), 3.78 (s, 3 H), 3.77
(dd, J = 3.2, 12.4 Hz, 1 H), 3.75 (d, J = 17.1 Hz, 1 H), 3.06 (dd, J = 9.0,
12.6 Hz, 1 H), 2.39 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 164.29, 159.15, 146.39, 144.54,
131.74, 130.28, 127.76, 126.62, 123.15, 121.5, 114.43, 75.82, 55.23,
50.7, 46.52, 43.59, 21.1.
HRMS (ESI): m/z [M + H]+ calcd for C21H23N4O5S: 443.13837; found:
443.13705.
6-{[4-(2-Fluorophenyl)-1H-1,2,3-triazol-1-yl]methyl}-4-tosylmor-
pholin-2-one (8d)
According to general procedure B, compound 8d was isolated after re-
crystallization (EtOH).
Yield: 533 mg (62%); white solid; mp 191–192 °C; Rf = 0.38 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.45 (d, J = 3.81 Hz, 1 H), 8.15 (td,
J = 1.7, 7.4 Hz, 1 H), 7.17 (d, J = 8.15 Hz, 2 H), 7.47 (d, J = 8.15 Hz, 2 H),
7.42–7.31 (m, 3 H), 5.08–5.00 (m, 1 H), 4.87–4.74 (m, 2 H), 4.01 (d, J =
17.0 Hz, 1 H), 3.78 (d, J = 17.0 Hz, 1 H), 3.73 (dd, J = 3.3, 12.3 Hz, 1 H),
3.10 (dd, J = 8.4, 12.6 Hz, 1 H), 2.39 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 164.14, 158.46 (d, J = 247 Hz),
144.42, 139.72 (d, J = 2.3 Hz), 131.70, 130.18, 127.27 (d, J = 3.4 Hz),
125.0 (d, J = 3.15 Hz), 124.77 (d, J = 11.7 Hz), 118.21 (d, J = 21.3 Hz),
116.05 (d, J = 21.3 Hz), 75.80, 50.71, 46.52, 43.49, 21.01.
19F NMR (282 MHz, DMSO-d6):  = –114.65.
HRMS (ESI): m/z [M + H]+ calcd for C20H20FN4O4S: 431.11893; found:
431.11709.
6-{[4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl]methyl}-4-tosylmor-
pholin-2-one (8e)
According to general procedure B, compound 8e was isolated after re-
crystallization (EtOH).
Yield: 705 mg (82%); white solid; mp 207–208 °C; Rf = 0.38 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.53 (s, 1 H), 7.87 (dd, J = 5.5,
8.8 Hz, 2 H), 7.70 (d, J = 8.2 Hz, 2 H), 7.46 (d, J = 8.2 Hz, 2 H), 7. 30 (t,
J = 8.9 Hz, 2 H), 5.00–5.05 (m, 1 H), 4.80 (dd, J = 3.8, 14.6 Hz, 1 H), 4.71
(dd, J = 7.3, 14.6 Hz, 1 H), 4.03 (d, J = 17.15 Hz, 1 H), 3.77 (dd, J = 3.1,
12.8 Hz, 1 H), 3.76 (d, J = 17.15 Hz, 1 H), 3.04 (dd, J = 8.8, 12.7 Hz, 1 H),
2.38 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 164.33, 161.95 (d, J = 244.5 Hz),
145.65, 144.6, 131.76, 130.32, 127.8, 127.43, 127.35 (d, J = 8.2 Hz),
127.17 (d, J = 3.1 Hz), 122.44, 116.02 (d, J = 22 Hz), 75.83, 50.82, 46.56,
43.61, 21.13.
19F NMR (282 MHz, DMSO-d6):  = –113.84.
HRMS (ESI): m/z [M + H]+ calcd for C2H20FN4O4S: 431.11838; found:
431.11736.
6-{[4-(2,4-Difluorophenyl)-1H-1,2,3-triazol-1-yl]methyl}-4-to-
sylmorpholin-2-one (8f)
According to general procedure B, compound 8f was isolated after re-
crystallization (EtOH).
Yield: 716 mg (80%); white solid; mp 213–214 °C; Rf = 0.35 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.44 (d, J = 3.55 Hz, 1 H), 8.20–8.12
(m, 1 H), 7.70 (d, J = 7.8 Hz, 2 H), 7.46 (d, J = 7.8 Hz, 2 H), 7.43–7.37
(m, 1 H), 7.27–7.20 (m, 1 H), 5.06–5.00 (m, 1 H), 4.84–4.76 (m, 2 H),
4.00 (d, J = 10.1 Hz, 1 H), 3.77 (d, J = 17.1 Hz, 1 H), 3.73 (dd, J = 2.8,
12.05 Hz, 1 H), 3.10 (dd, J = 8.5, 12.6 Hz, 1 H), 2.39 (s, 3 H).Georg Thieme Verlag  Stuttgart · New York — SynOpen 2018, 2, 298–305
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247.3 Hz), 158.49 (dd, J = 12.7, 248.6 Hz), 144.41, 139.12 (d, J =
2.2 Hz), 131.70, 130.15, 128.50 (dd, J = 5.2, 9.7 Hz), 127.68, 124.41 (d,
J = 11.1 Hz), 115.03 (dd, J = 3.75, 13.4 Hz), 112.30 (dd, J = 3.25,
21.3 Hz), 104.56 (t, J = 26 Hz), 75.79, 50.74, 46.51, 43.48, 20.99.
19F NMR (282 MHz, DMSO-d6):  = –110.56 (d, J = 7.7 Hz), –110.35 (d,
J = 7.7 Hz).
HRMS (ESI): m/z [M + H]+ calcd for C21H22N4O4S: 449.10896; found:
449.10778.
6-{[4-(Pyridin-2-yl)-1H-1,2,3-triazol-1-yl]methyl}-4-tosylmor-
pholin-2-one (8g)
According to general procedure B, compound 8g was isolated after re-
crystallization (EtOH).
Yield: 454 mg (55%); white solid; mp 225–226 °C; Rf = 0.37 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.65–8.59 (m, 2 H), 8.05 (d, J =
7.6 Hz, 1 H), 7.91 (t, J = 7.2 Hz, 1 H), 7.71 (d, J = 8.1 Hz, 2 H), 7.47 (d, J =
8.1 Hz, 2 H), 7.39–7.35 (m, 1 H), 5.06–5.00 (m, 1 H), 4.87–4.74 (m,
2 H), 4.02 (d, J = 17.1 Hz, 1 H), 3.79 (d, J = 17.1 Hz, 1 H), 3.75 (dd, J =
3.1, 12.5 Hz, 1 H), 3.11 (dd, J = 8.6, 12.5 Hz, 1 H), 2.39 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 175.38, 155.16, 148.33, 145.94,
141.92, 141.82, 137.66, 134.85, 132.63, 132.17, 128.94, 124.34, 88.25,
85.08, 55.78, 52.53, 26.13.
HRMS (ESI): m/z [M + H]+ calcd for C19H20N5O4S: 414.12305; found:
414.12213.
6-[{4-[4-(Dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}methyl]-
4-tosylmorpholin-2-one (8h)
According to general procedure B, compound 8h was isolated after re-
crystallization (EtOH).
Yield: 609 mg (67%); white solid; mp 237–238 °C; Rf = 0.35 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 8.32 (s, 1 H), 7.70 (d, J = 8.2 Hz,
2 H), 7.64 (d, J = 8.7 Hz, 2 H), 7.46 (d, J = 8.2 Hz, 2 H), 6.78 (d, J =
8.7 Hz, 2 H), 5.05–4.97 (m, 1 H), 4.74 (dd, J = 3.8, 14.6 Hz, 1 H), 4.67
(dd, J = 7.3, 14.6 Hz), 4.04 (d, J = 17.1 Hz, 1 H), 3.77 (dd, J = 8.9,
12.6 Hz, 1 H), 3.75 (d, J = 17.1 Hz, 1 H), 3.06 (dd, J = 8.9, 12.6 Hz, 1 H),
2.93 (s, 6 H), 2.39 (s, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 164.22, 150.09, 147.02, 144.44,
131.73, 130.2, 127.7, 126.1, 120.47, 118.4, 112.36, 75.81, 50.56, 46.47,
43.56, 21.04.
HRMS (ESI): m/z [M + H]+ calcd for C22H26N5O4S: 456.17000; found:
456.16862.
6-[(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)methyl]-4-tosylmor-
pholin-2-one (8i)
According to general procedure B, compound 8i was isolated after re-
crystallization (EtOH).
Yield: 564 mg (75%); white solid; mp 177–178 °C; Rf = 0.35 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 7.80 (s, 1 H), 7.70 (d, J = 8.2 Hz,
2 H), 7.48 (d, J = 8.2 Hz, 2 H), 4.95–4.88 (m, 1 H), 4.65 (dd, J = 3.9,
14.6 Hz, 1 H), 4.57 (dd, J = 7.5, 14.6 Hz, 1 H), 4.01 (d, J = 17.1 Hz, 1 H),
3.72 (d, J = 17.1 Hz, 1 H), 3.70 (dd, J = 3.2, 12.6 Hz, 1 H), 3.00 (dd, J =
8.8, 12.6 Hz, 1 H), 2.42 (s, 3 H), 1.98–1.88 (m, 1 H), 0.92–0.86 (m, 2 H),
0.72–0.67 (m, 2 H).
13C NMR (75 MHz, DMSO-d6):  = 164.16, 148.91, 144.45, 131.71,
130.2, 127.7, 121.78, 75.85, 69.69, 50.4, 46.45, 43.53, 21.06, 7.61, 6.44.
HRMS (ESI+): m/z [M + H]+ calcd for C17H21N4O4S: 377.12830; found:
377.12731.
N-Butyl-4-methyl-N-({1-[(6-oxo-4-tosylmorpholin-2-yl)methyl]-
1H-1,2,3-triazol-4-yl}methyl)benzenesulfonamide (8j)
According to general procedure B, compound 8j was isolated after re-
crystallization (EtOH).
Yield: 851 mg (74%); white solid; mp 179–180 °C; Rf = 0.33 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, DMSO-d6):  = 7.95 (s, 1 H), 7.71 (d, J = 8.2 Hz,
2 H), 7.66 (d, J = 8.2 Hz, 2 H), 7.48 (d, J = 8.1 Hz, 2 H), 7.37 (d, J =
8.1 Hz, 2 H), 4.93–4.87 (m, 1 H), 4.73–4.61 (m, 2 H), 4.37 (s, 2 H), 4.03
(d, J = 17.2 Hz, 1 H), 3.72 (dd, J = 2.9, 12.4 Hz, 1 H), 3.71 (d, J = 17.2 Hz,
1 H), 2.95–3.07 (m, 3 H), 2.42 (s, 3 H), 2.38 (s, 3 H), 1.40–1.30 (m, 2 H),
1.15–1.07 (m, 2 H), 0.74 (t, J = 7.27 Hz, 3 H).
13C NMR (75 MHz, DMSO-d6):  = 163.98, 144.48, 143.08, 142.94,
136.29, 131.7, 130.21, 129.72, 127.68, 126.93, 124.89, 75.91, 50.54,
47.32, 46.84, 43.52, 42.33, 29.54, 21.04, 20.94, 19.05, 13.39.
HRMS (ESI): m/z [M + H]+ calcd for C26H34N5O6S2: 576.19450; found:
576.19292.
N-Allyl-4-methyl-N-{1-[(6-oxo-4-tosylmorpholin-2-yl)methyl]-
1H-1,2,3-triazol-4-yl}benzenesulfonamide (8k)
According to general procedure B, compound 8k was isolated after
flash chromatography.
Yield: 771 mg (69%); white solid; mp 157–158 °C; Rf = 0.35 (EtOAc/PE
= 4:1).
1H NMR (300 MHz, acetone-d6):  = 7.83 (s, 1 H), 7.72 (d, J = 8.0 Hz,
2 H), 7.69 (d, J = 8.0 Hz, 2 H), 7.48 (d, J = 8.4 Hz, 2 H), 7.37 (d, J =
8.4 Hz, 2 H), 5.60 (ddt, J = 6.3, 10.2, 17.1 Hz, 1 H), 5.15 (dq, J = 1.5,
17.1 Hz, 1 H), 5.05 (dq, J = 1.6, 10.2 Hz, 1 H), 5.03–4.96 (m, 1 H), 4.84–
4.71 (m, 2 H), 4.43 (s, 2 H), 4.03 (d, J = 17.3 Hz, 2 H), 3.84–3.76 (m,
2 H), 3.10 (dd, J = 8.3, 12.8 Hz, 2 H), 2.42 (s, 3 H), 2.39 (s, 3 H).
13C NMR (75 MHz, acetone-d6):  = 164.27, 145.67, 144.29, 138.44,
133.51, 131.1, 130.62, 128.89, 128.18, 119.14, 77.28, 70.82, 51.93,
50.73, 47.58, 44.95, 42.48, 21.85, 21.49.
HRMS (ESI): m/z [M + H]+ calcd for C25H30N5O6S2: 560.16320; found:
560.16186.
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